DRB18 |
Catalog No.GC64568 |
DRB18 es un potente inhibidor de GLUT de clase pan. DRB18 altera el metabolismo relacionado con la energÍa en las células A549 al cambiar la abundancia de metabolitos en las vÍas relacionadas con la glucosa. DRB18 puede conducir eventualmente a la detenciÓn de la fase G1/S y aumentar el estrés oxidativo y la muerte celular necrÓtica. DRB18 tiene actividad antitumoral.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity[1].
DRB18 (0-10 μM; 30 min) reduces glucose uptake in GLUT1-4-expressed HEK293 cell lines in a dose-dependent manner with IC50s varying from ~ 900 nM to ~ 9 μM[1].DRB18 (5 and 10 μM; 72 hours) causes cell cycle arrest in the G1/S phase transition[1].DRB18 (5 and 10 μM; 72 hours) increases ROS levels in A549 cells[1].DRB18 (5 and 10 μM; 72 hours) reduces expression of glycosylated GLUT1 and GLUT2-4 in A549 cells in a dose-dependent manner[1].
DRB18 (10 mg/kg; IP; thrice a week for 5 weeks) inhibits tumors volume by 44% and tumors weight by 43%[1].
[1]. Shriwas P, Roberts D, Li Y, et al. A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism. Cancer Metab. 2021;9(1):14. Published 2021 Mar 26.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *